Supreme Court rejects appeals from drug manufacturers over Medicare price negotiations with government
The negotiation program was created as part of the 2022 Inflation Reduction Act, which capped years of debate over whether the federal government should be allowed to haggle directly with manufacturers over the prices of drugs in Medicare.
The negotiation program was created as part of the 2022 Inflation Reduction Act, which capped years of debate over whether the federal government should be allowed to haggle directly with manufacturers over the prices of drugs in Medicare.
The negotiation program was created as part of the 2022 Inflation Reduction Act, which capped years of debate over whether the federal government should be allowed to haggle directly with manufacturers over the prices of drugs in Medicare.
The full story continues on PBS News.
Story Sentry shows a short summary aggregated via RSS. The complete article — original photography, charts, and reporting — lives with the publisher.